{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:04:25Z","timestamp":1790564665835,"version":"4.1.0"},"reference-count":18,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Epidemiological studies have demonstrated the association between hepatitis B virus (HBV) infection and B-cell non\u2013Hodgkin lymphoma (NHL), mainly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). We studied a cohort of 121 patients with FL for HBV infection status, clinical features, and gene mutational profile. Anti-HBc was detectable in 16 patients (13.2%), although all had undetectable HBV DNA. Anti-HBcore+ (anti-HBc+) cases presented with older age at diagnosis than anti-HBc\u2212 cases (68.1 vs 57.2 years; P = .007) and higher \u03b22-microglobulin (56.3% vs 28.9%; P = .04). All patients included in the study fulfilled criteria for treatment and received therapy with rituximab or rituximab-containing chemotherapy. There were no episodes of HBV reactivation or HBV hepatitis during treatment and\/or maintenance. Remarkably, anti-HBc+ patients had significantly lower 10-year progression-free survival (PFS; 12.9% vs 58.3%; P &amp;lt; .0001) and overall survival (OS; 22.0% vs 86.2%; P &amp;lt; .0001), that remained at multivariate analysis. Gene mutational profiling of all cases showed that anti-HBc+ cases had higher incidence of ARID1A mutations and absence of EP300 mutations, 2 key epigenetic regulators in FL. Overall, our study shows that FL patients with resolved HBV infection have a worse outcome independently of other well-known clinical risk factors and a distinct gene mutational profile.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005316","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T01:54:29Z","timestamp":1634694869000},"page":"82-86","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-0843","authenticated-orcid":false,"given":"Concepci\u00f3n","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Department of Pathology, Hospital del Mar\u2013Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain;"},{"name":"Group of Applied Clinical Research in Hematology, Cancer Research Program-IMIM, Barcelona, Spain;"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Rodr\u00edguez-Sevilla","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital del Mar-IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lierni","family":"Fern\u00e1ndez-Ibarrondo","sequence":"additional","affiliation":[{"name":"Group of Applied Clinical Research in Hematology, Cancer Research Program-IMIM, Barcelona, Spain;"},{"name":"Department of Experimental Science and Health, Pompeu Fabra University, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"S\u00e1nchez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Group of Applied Clinical Research in Hematology, Cancer Research Program-IMIM, Barcelona, Spain;"},{"name":"Department of Hematology, Hospital del Mar-IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-0759","authenticated-orcid":false,"given":"Joan","family":"Gibert","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital del Mar\u2013Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain;"},{"name":"Group of Applied Clinical Research in Hematology, Cancer Research Program-IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Bento","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Son Espases, Mallorca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6974-0806","authenticated-orcid":false,"given":"Juan Fernando","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Pathology, MD Anderson Cancer Center, Madrid, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-6538","authenticated-orcid":false,"given":"Juan Manuel","family":"Sancho","sequence":"additional","affiliation":[{"name":"Department of Hematology, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Diez-Feij\u00f3o","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital del Mar-IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Camacho","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital del Mar\u2013Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain;"},{"name":"Group of Applied Clinical Research in Hematology, Cancer Research Program-IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-7604","authenticated-orcid":false,"given":"Montserrat","family":"Garc\u00eda-Retortillo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital del Mar-IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3534-6189","authenticated-orcid":false,"given":"Eva","family":"Gimeno","sequence":"additional","affiliation":[{"name":"Group of Applied Clinical Research in Hematology, Cancer Research Program-IMIM, Barcelona, Spain;"},{"name":"Department of Hematology, Hospital del Mar-IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-5085","authenticated-orcid":false,"given":"Luis","family":"Colomo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital del Mar\u2013Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain;"},{"name":"Department of Experimental Science and Health, Pompeu Fabra University, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Son Espases, Mallorca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5335-2726","authenticated-orcid":false,"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital del Mar\u2013Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain;"},{"name":"Group of Applied Clinical Research in Hematology, Cancer Research Program-IMIM, Barcelona, Spain;"},{"name":"Department of Experimental Science and Health, Pompeu Fabra University, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4652-4825","authenticated-orcid":false,"given":"Antonio","family":"Salar","sequence":"additional","affiliation":[{"name":"Group of Applied Clinical Research in Hematology, Cancer Research Program-IMIM, Barcelona, Spain;"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain;"},{"name":"Department of Hematology, Hospital del Mar-IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"1","key":"2022010416204340000_B1","doi-asserted-by":"crossref","first-page":"14516","DOI":"10.1038\/s41598-019-51157-1","article-title":"Pro-oncogenic, intra host viral quasispecies in diffuse large B cell lymphoma patients with occult hepatitis B virus infection","volume":"9","author":"Sinha","year":"2019","journal-title":"Sci Rep."},{"issue":"8","key":"2022010416204340000_B2","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/ijc.33027","article-title":"Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma","volume":"147","author":"L","year":"2020","journal-title":"Int J Cancer."},{"issue":"8","key":"2022010416204340000_B3","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/jvh.12892","article-title":"Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta-analysis of 58 studies","volume":"25","author":"Li","year":"2018","journal-title":"J Viral Hepat."},{"issue":"6","key":"2022010416204340000_B4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00277-008-0469-9","article-title":"High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin\u2019s lymphoma","volume":"87","author":"Chen","year":"2008","journal-title":"Ann Hematol."},{"issue":"1","key":"2022010416204340000_B5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1471-2407-8-115","article-title":"Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2008","journal-title":"BMC Cancer."},{"issue":"24","key":"2022010416204340000_B6","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood-2017-11-817601","article-title":"Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma","volume":"131","author":"Ren","year":"2018","journal-title":"Blood"},{"key":"2022010416204340000_B7","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2147\/CMAR.S244381","article-title":"Clinical analysis and prognostic significance of hepatitis B virus infections with diffuse large B-cell lymphoma","volume":"12","author":"K","year":"2020","journal-title":"Cancer Manag Res."},{"issue":"3","key":"2022010416204340000_B8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol."},{"issue":"14","key":"2022010416204340000_B9","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2008-10-163493","article-title":"How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation","volume":"113","author":"Liang","year":"2009","journal-title":"Blood."},{"issue":"10","key":"2022010416204340000_B10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jvh.12402","article-title":"Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis","volume":"22","author":"Mozessohn","year":"2015","journal-title":"J Viral Hepat."},{"issue":"2","key":"2022010416204340000_B11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"Blood."},{"issue":"4","key":"2022010416204340000_B12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/v9040075","article-title":"HBV DNA integration: molecular mechanisms and clinical implications","volume":"9","author":"Tu","year":"2017","journal-title":"Viruses."},{"issue":"9","key":"2022010416204340000_B13","doi-asserted-by":"crossref","first-page":"e0162586","DOI":"10.1371\/journal.pone.0162586","article-title":"Accumulation of deleterious passenger mutations is associated with the progression of hepatocellular carcinoma","volume":"11","author":"Budzinska","year":"2016","journal-title":"PLoS One."},{"issue":"2","key":"2022010416204340000_B14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet."},{"issue":"9","key":"2022010416204340000_B15","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"2022010416204340000_B16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00281-020-00780-6","article-title":"Epigenetic modulation in chronic hepatitis B virus infection","volume":"42","author":"Dandri","year":"2020","journal-title":"Semin Immunopathol."},{"issue":"JUL","key":"2022010416204340000_B17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fgene.2018.00261","article-title":"Host and viral genetic variation in HBV-related hepatocellular carcinoma","volume":"9","author":"An","year":"2018","journal-title":"Front Genet."},{"issue":"JAN","key":"2022010416204340000_B18","first-page":"1491","article-title":"The epigenetic control of hepatitis B virus modulates the outcome of infection","volume":"6","author":"Koumbi","year":"2016","journal-title":"Front Microbiol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/1\/82\/1856735\/advancesadv2021005316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/1\/82\/1856735\/advancesadv2021005316.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T16:22:58Z","timestamp":1641313378000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/1\/82\/477314\/Worse-outcome-and-distinct-mutational-pattern-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005316","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]}}}